{"id":"https://openalex.org/W2802449276","doi":"https://doi.org/10.1158/1078-0432.ccr-17-3421","title":"A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer","display_name":"A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer","publication_year":2018,"publication_date":"2018-04-10","ids":{"openalex":"https://openalex.org/W2802449276","doi":"https://doi.org/10.1158/1078-0432.ccr-17-3421","mag":"2802449276","pmid":"https://pubmed.ncbi.nlm.nih.gov/29636360"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-17-3421","doi":"https://doi.org/10.1158/1078-0432.ccr-17-3421","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-17-3421","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028472820","display_name":"Johanna C. Bendell","orcid":"https://orcid.org/0000-0001-9426-5891","observed_orcids":["https://orcid.org/0000-0001-9426-5891"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Johanna C. Bendell","raw_affiliation_strings":["1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027467209","display_name":"Anna M. Varghese","orcid":"https://orcid.org/0000-0001-5426-0885","observed_orcids":["https://orcid.org/0000-0001-5426-0885"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna M. Varghese","raw_affiliation_strings":["2Memorial Sloan Kettering Cancer Center, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Memorial Sloan Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068193017","display_name":"David Michael Hyman","orcid":"https://orcid.org/0000-0001-8150-9762","observed_orcids":["https://orcid.org/0000-0001-8150-9762"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Hyman","raw_affiliation_strings":["2Memorial Sloan Kettering Cancer Center, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Memorial Sloan Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037195922","display_name":"Todd Michael Bauer","orcid":"https://orcid.org/0000-0002-3078-5043","observed_orcids":["https://orcid.org/0000-0002-3078-5043"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd M. Bauer","raw_affiliation_strings":["1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084349853","display_name":"Shubham Pant","orcid":"https://orcid.org/0000-0001-9281-480X","observed_orcids":["https://orcid.org/0000-0001-9281-480X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shubham Pant","raw_affiliation_strings":["3Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051346978","display_name":"Sophie Callies","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sophie Callies","raw_affiliation_strings":["4Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053450523","display_name":"Ji Lin","orcid":"https://orcid.org/0000-0001-7206-6111","observed_orcids":["https://orcid.org/0000-0001-7206-6111"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ji Lin","raw_affiliation_strings":["4Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":"https://orcid.org/0000-0001-7206-6111","affiliations":[{"raw_affiliation_string":"4Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109760957","display_name":"Ricardo Mart\u00ednez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ricardo Martinez","raw_affiliation_strings":["4Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035801178","display_name":"Enaksha R. Wickremsinhe","orcid":"https://orcid.org/0009-0003-0609-823X","observed_orcids":["https://orcid.org/0009-0003-0609-823X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Enaksha Wickremsinhe","raw_affiliation_strings":["4Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051542505","display_name":"Aaron Alan Fink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron Fink","raw_affiliation_strings":["4Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009244604","display_name":"Volker Wacheck","orcid":"https://orcid.org/0000-0003-3962-5932","observed_orcids":["https://orcid.org/0000-0003-3962-5932"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Volker Wacheck","raw_affiliation_strings":["4Eli Lilly and Company, Indianapolis, Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Eli Lilly and Company, Indianapolis, Indiana","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069337573","display_name":"Kathleen N. Moore","orcid":"https://orcid.org/0000-0002-5803-0718","observed_orcids":["https://orcid.org/0000-0002-5803-0718"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathleen N. Moore","raw_affiliation_strings":["3Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Stephenson Oklahoma Cancer Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5028472820"],"corresponding_institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"],"apc_list":null,"apc_paid":null,"fwci":4.3542,"has_fulltext":false,"cited_by_count":110,"citation_normalized_percentile":{"value":0.96024801,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":100},"biblio":{"volume":"24","issue":"14","first_page":"3253","last_page":"3262"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dual-pi3k-mtor-inhibitor","display_name":"PI3K/mTOR dual inhibitor","score":0.949999988079071},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.9350000023841858},{"id":"https://openalex.org/keywords/dna-pk-inhibition","display_name":"DNA-PK inhibition","score":0.9409999847412109},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.7789999842643738},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8240000009536743},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.8899999856948853},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8769999742507935},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8610000014305115},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8899999856948853},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.824999988079071},{"id":"https://openalex.org/keywords/pik3r1-mutation","display_name":"PIK3R1 mutation","score":0.9110000133514404}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7864514589309692},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.7531371712684631},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6795628070831299},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.6676284074783325},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6491432189941406},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.603678822517395},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5452842712402344},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5239686965942383},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.48857077956199646},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44095703959465027},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4319286048412323},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3525027632713318},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.2859123945236206}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-17-3421","doi":"https://doi.org/10.1158/1078-0432.ccr-17-3421","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-17-3421","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:29636360","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29636360","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1967013964","https://openalex.org/W1992477322","https://openalex.org/W2001999652","https://openalex.org/W2006771504","https://openalex.org/W2010559088","https://openalex.org/W2019607817","https://openalex.org/W2027798661","https://openalex.org/W2032500497","https://openalex.org/W2038444072","https://openalex.org/W2041440766","https://openalex.org/W2059788609","https://openalex.org/W2067019627","https://openalex.org/W2076293231","https://openalex.org/W2097665491","https://openalex.org/W2116761906","https://openalex.org/W2123540640","https://openalex.org/W2126783165","https://openalex.org/W2129159987","https://openalex.org/W2141125222","https://openalex.org/W2150174916","https://openalex.org/W2160981405","https://openalex.org/W2165404212","https://openalex.org/W2167264978","https://openalex.org/W2283437222","https://openalex.org/W2497200850","https://openalex.org/W2518718875","https://openalex.org/W2788744735","https://openalex.org/W6677382729"],"related_works":["https://openalex.org/W2598882746","https://openalex.org/W3036375657","https://openalex.org/W2497200850","https://openalex.org/W2104243174","https://openalex.org/W2802053092","https://openalex.org/W2126390772","https://openalex.org/W2771798167","https://openalex.org/W2590160203","https://openalex.org/W1979937839","https://openalex.org/W2076670881"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"The":[2,67,234],"PI3K/mTOR":[3],"pathway":[4],"is":[5,11,239],"frequently":[6],"aberrated":[7],"in":[8,115,126,132,164,191,211,229],"cancer.":[9],"LY3023414":[10,54,94,159,178,220,237],"a":[12,181,192,209,222],"potent":[13],"and":[14,24,41,49,84,131,150,153,199,203,226,248],"selective":[15],"ATP-competitive":[16],"inhibitor":[17,183],"of":[18,32,38,53,117,128,134,184,236],"class":[19],"I":[20,36],"PI3K":[21],"isoforms,":[22],"mTOR,":[23],"DNA-PK.":[25],"Here":[26],"we":[27],"report":[28],"the":[29,33,73],"dose-escalation":[30],"results":[31],"first-in-human":[34],"phase":[35,75],"study":[37],"LY3023414.":[39],"Patients":[40],"Methods:":[42],"A":[43],"3+3":[44],"dose":[45,77],"escalation":[46],"for":[47,61],"once-daily":[48,96,111],"twice-daily":[50,100,121,140],"oral":[51],"dosing":[52,101,122],"was":[55,70,189],"followed":[56],"by":[57,215],"an":[58],"expansion":[59],"cohort":[60],"CYP3A4":[62],"drug\u2013drug":[63],"interaction":[64],"(DDI)":[65],"assessment.":[66],"primary":[68],"objective":[69],"to":[71,179,217],"determine":[72],"recommended":[74],"2":[76],"(RP2D).":[78],"Additional":[79],"objectives":[80],"included":[81,145],"safety,":[82,246],"pharmacokinetics/pharmacodynamics,":[83],"antitumor":[85],"activity.":[86],"Results:":[87],"Forty-seven":[88],"patients":[89,136,206,230],"with":[90,166,194,231],"solid":[91],"tumors":[92],"received":[93],"at":[95,108,137,171],"(20\u2013450":[97],"mg)":[98],"or":[99,157],"(150\u2013250":[102],"mg).":[103],"Dose-limiting":[104],"toxicities":[105],"were":[106,154],"observed":[107,190],"450":[109],"mg":[110,139,241],"(thrombocytopenia,":[112],"hypotension,":[113],"hyperkalemia)":[114],"three":[116,118,127],"patients,":[119,130],"250-mg":[120],"(hypophosphatemia,":[123],"fatigue,":[124],"mucositis)":[125],"four":[129],"one":[133],"15":[135],"200":[138,240],"(nausea).":[141],"Common":[142],"related":[143],"AEs":[144],"nausea":[146],"(38%),":[147],"fatigue":[148],"(34%),":[149],"vomiting":[151],"(32%)":[152],"mostly":[155],"mild":[156],"moderate.":[158],"pharmacokinetics":[160],"demonstrated":[161,177],"dose-dependent":[162],"increase":[163],"exposure":[165],"\u2265":[167],"90%":[168],"target":[169,213],"inhibition":[170],"doses":[172],"\u2265150":[173],"mg.":[174],"DDI":[175],"analysis":[176],"be":[180],"weak":[182],"CYP3A4.":[185],"Durable":[186],"partial":[187],"response":[188],"patient":[193],"endometrial":[195],"cancer":[196],"harboring":[197],"PIK3R1":[198],"PTEN":[200],"truncating":[201],"mutations,":[202],"13":[204],"additional":[205],"(28%)":[207],"had":[208],"decrease":[210],"their":[212],"lesions":[214],"up":[216],"30%.":[218],"Conclusions:":[219],"has":[221],"tolerable":[223],"safety":[224],"profile":[225],"single-agent":[227],"activity":[228],"advanced":[232],"cancers.":[233],"RP2D":[235],"monotherapy":[238],"twice":[242],"daily":[243],"based":[244],"on":[245],"tolerability,":[247],"pharmacokinetic/pharmacodynamic":[249],"data.":[250],"Clin":[251],"Cancer":[252],"Res;":[253],"24(14);":[254],"3253\u201362.":[255],"\u00a92018":[256],"AACR.":[257]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":21},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":19},{"year":2021,"cited_by_count":22},{"year":2020,"cited_by_count":20},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-05-17T00:00:00"}